Krystal Biotech Inc (KRYS)

Payables turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cost of revenue (ttm) US$ in thousands 113,685 104,592 99,576 97,854 96,536 95,405 91,643 83,602 75,785 65,603 55,240 47,176 38,941 31,446 26,454 19,970 13,729 12,173 9,050 7,409
Payables US$ in thousands 4,985 5,580 5,425 5,359 4,132 4,340 4,446 4,109 3,981 5,761 9,229 8,209 8,398 4,757 1,265 1,844 2,105 2,591 1,613 636
Payables turnover 22.81 18.74 18.36 18.26 23.36 21.98 20.61 20.35 19.04 11.39 5.99 5.75 4.64 6.61 20.91 10.83 6.52 4.70 5.61 11.65

December 31, 2024 calculation

Payables turnover = Cost of revenue (ttm) ÷ Payables
= $113,685K ÷ $4,985K
= 22.81

The payables turnover ratio measures how efficiently a company pays its suppliers by comparing the company's cost of goods sold to its average accounts payable balance. A higher payables turnover ratio indicates that the company is paying its suppliers more quickly.

Analyzing the payables turnover data of Krystal Biotech Inc from March 31, 2020, to December 31, 2024, reveals fluctuations in the efficiency of the company's payable management over time. The ratio ranged from a low of 4.64 on December 31, 2021, to a high of 23.36 on December 31, 2023.

The trend in the payables turnover ratio shows variability, with spikes in efficiency followed by declines in subsequent periods. The ratio increased significantly from June 30, 2021, to December 31, 2023, indicating that the company was quicker in paying its suppliers during this period. However, there was a decrease in efficiency in the subsequent periods up to December 31, 2024.

Overall, the payables turnover ratio for Krystal Biotech Inc shows fluctuations over the years, indicating varying levels of effectiveness in managing its accounts payable. It is important for the company to consistently monitor and optimize its payable turnover to maintain healthy supplier relationships and working capital management.